Company Profiles

driven by the PitchBook Platform

DNAtrix

Description

Developer of virus-driven immunotherapies for cancer. The company's lead product, DNX-2401, is a conditionally replicative oncolytic virus being studied in clinical trials for recurrent glioblastoma, an incurable brain cancer and the company's pipeline includes viruses armed with potent immunomodulatory molecules that augment a patient’s immune system to trigger an aggressive anti-tumor T-cell response.

2005

Founded

PRIVATE

Status

11-50

Employees

Series B

Latest Deal Type

$19.8M

Latest Deal Amount

$21.8M

Total Amount Raised

Description

Developer of virus-driven immunotherapies for cancer. The company's lead product, DNX-2401, is a conditionally replicative oncolytic virus being studied in clinical trials for recurrent glioblastoma, an incurable brain cancer and the company's pipeline includes viruses armed with potent immunomodulatory molecules that augment a patient’s immune system to trigger an aggressive anti-tumor T-cell response.

Website:

www.dnatrix.com

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Biotechnology

Primary Office

2450 Holcombe Boulevard Houston, TX 77021United States +1 (832) 930-2401
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore DNAtrix's full profile, request a free trial.

DNAtrix Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

DNAtrix Cap Table

Stock# of Shares
Authorized
Par ValueDividend Rate (%)Original
Issue Price
LiquidationLiquidation
Pref. Multiple
Conversion
Price
% Owned

DNAtrix Investors (9)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
CPRITOtherMinority000 0000000 0000
JLabsAccelerator/IncubatorMinority000 0000000 0000
Mercury FundVenture CapitalMinority000 0000000 0000
Morningside GroupVenture CapitalMinority000 0000000 0000
Targeted TechnologyVenture CapitalMinority000 0000000 0000
CPRIT Other
JLabs Accelerator/Incubator
Mercury Fund Venture Capital
Morningside Group Venture Capital
Targeted Technology Venture Capital

DNAtrix Executive Team (12)

NameTitleBoard
Seat
Contact
Info
Frank Tufaro Ph.DChief Executive Officer & Board Member
Brian MooneyChief Financial Officer
Imran Alibhai Ph.DManaging Director & Senior Vice President, Business Development
Imre Kovesdi Ph.DChief Scientific Officer & Senior Vice President, Research
Erin Mitchell Ph.DVice President, Manufacturing & Director, Manufacturing
Frank Tufaro Ph.D Chief Executive Officer & Board Member
Brian Mooney Chief Financial Officer
Imran Alibhai Ph.D Managing Director & Senior Vice President, Business Development
Imre Kovesdi Ph.D Chief Scientific Officer & Senior Vice President, Research
Erin Mitchell Ph.D Vice President, Manufacturing & Director, Manufacturing

DNAtrix Board Members (5)

NameRepresentingRoleSinceContact
Info
Daniel Watkins Ph.DMercury FundCo-Founder & Partner000 0000
Drew Pardoll Ph.DDNAtrixBoard Member000 0000
Francis McCormickSelfBoard Member000 0000
Frank Tufaro Ph.DDNAtrixChief Executive Officer & Board Member000 0000
Reenie McCarthy JDMorningside GroupDirector000 0000
Daniel Watkins Ph.D Co-Founder & Partner Mercury Fund
Drew Pardoll Ph.D Board Member DNAtrix
Francis McCormick Board Member Self
Frank Tufaro Ph.D Chief Executive Officer & Board Member DNAtrix
Reenie McCarthy JD Director Morningside Group
Request full access to PitchBook